ArticlesArchiveAboutEditorial BoardAuthor Guidelines
Call for papersThe 2026 special issue on Climate & Health is open for submissions.Learn more
JCT is an international journal dedicated to the latest advancements in cancer therapy. The goal of this journal is to provide a platform for doctors and academicians all over the world to promote, share, and discuss various new issues and developments in cancer related problems. All manuscripts must be prepared in En…
Ryouichi Tomita, Kenichi Sakurai, Shigeru Fujisaki
Objectives: To clarify the optimal length of the antral cuff (LAC) in patients after pylorus-preserving gastrectomy (PPG), we investigated relationships between LAC and postgastrectomy disorder (PGD) such as postprandial abdominal fullness (PAF), and between…
Mariane Campagnari, Helio Alberto Carneiro, Andrea Schiavinato Jafelicci, Heidy Carmecide da Silva Reis, Elimar Elias Gomes, Eduardo Bertolli, João Pedreira Duprat Neto
Background: Standard treatment for subungual melanoma is wide local excision including digit amputation in order to obtain safety margins. Level of amputation has been discussed in order to achieve appropriate oncological results along with preservation of li…
Yongxin Zhang, Ying Wang, Zhenying Wang, Farhang Farhangfar, Monica Zimmerman
Variable bioreactors have been developed for the evaluation of anti-cancer drug efficacy. The Kinetic and Static Alternating Cell Culture System (KSACCS) combines the advantages of kinetic bioreactors and static cultures to improve cell growth by providing ad…
B. J. Srinivasa, L. P. Bhanu, Girish Badarke, Mohammad Nasiruddin, Sulav Sapkota, D. Tousif, Vishal Kulkarni, P. K. Kiran, Vinu Sarathy, G. S. Deepika, Amritanshu Ram, Raghavendra Rao, Shekar Patil, Radheshyam Naik
Background: Lung cancer is the leading cause of cancer-related death worldwide with an estimated 1.6 million new cases diagnosed each year. According to standard guidelines in NSCLC, the effectiveness of combin ed chemotherapy regimen comprises of pemetrexed…
Yuki Morishita, Hiroaki Tanioka, Motoi Asano, Kotomi Tokuyama, Hiroko Okamoto, Tomohisa Okamoto, Takako Oda, Masatoshi Ohta, Masayuki Fukuzawa
Predictive factors of cetuximab efficacy for metastatic colorectal cancer (mCRC) have not been sufficiently revealed. The present study aimed to explore new predictors. A total of 30 patients with KRAS exon 2 wild-type unresectable mCRC, who had been treated…
Marcio Debiasi, Franklin Fernandes Pimentel, Paula Juliana Seadi Pereira, Carlos H. Barrios, 1 1
Cancer is a major public health issue worldwide, especially in the developing world where 70% of the cancer-related deaths occur. During the last three decades, with the advent of targeted therapies using monoclonal antibodies, patients’ survival and quality…
Heba A. Sayed, Abeer Refaiy, Mohammed A. Salem
Aim: Wilms tumor (WT) is the most frequent type of pediatric renal tumors. Her/2 is an oncoprotein, its over-expression revealed to play a very vital role in the progress and improvement of certain tumors. This study evaluates the possible role of Her/2 as a…
Masahiro Kitada, Shunsuke Yasuda, Masahiro Abe, Nana Takahashi, Satoshi Okazaki, Kei Ishibashi, Satoshi Hayashi
Introduction : Neuroendocrine carcinoma (NEC) occurs mostly in the digestive organs, such as the pancreas and gastrointestinal tract, and the lungs. Primary NEC of the breast is a rare entity. There are not many studies on this disease, and this study was car…
Touré Moctar, Kouassi Kouamé K. Yvon, Séka E. Narcisse, Traoré Kady, Kimso Oumou, Niang D. Rokhaya, Odo B. Adde, Oseni Jelili, Adoubi Innocent
In our daily practice, the use of targeted therapies (Bevacizumab and rarely Cetuximab) in metastatic colic cancers is recent. Very few patients benefit from these therapies because of their high cost. In a cohort of 68 patients who received these therapies,…
Kalman Filanovsky, Edit Feldberg, Edward B. Miller, Lev Shvidel
Bone marrow (BM) metastases are known to worsen the outcome in patients with malignancies and alter the choice of the treatment regimen. In an attempt to identify routine parameters for the prediction of BM metastasis we evaluated the clinical and laboratory…
No articles in this issue.
JCT is an international journal dedicated to the latest advancements in cancer therapy. The goal of this journal is to provide a platform for doctors and academicians all over the world to promote, share, and discuss various new issues and developments in cancer related problems. All manuscripts must be prepared in En… All articles are open access under a CC BY 4.0 licence, with authors retaining copyright.
Authors submit their manuscript, metadata, and declarations through the portal. There is no submission fee.
The editorial office screens the manuscript for scope, completeness, and formatting before assigning a handling editor.
At least two independent reviewers evaluate the manuscript under single-blind review. Where revisions are required, authors respond point by point.
On acceptance the article processing charge is invoiced and the CC BY 4.0 copyright handover is signed.
The article is copyedited, typeset, and given a DOI, then publishes open access with a permanent link.
Manuscripts must be original and not under consideration elsewhere. Submit in Microsoft Word or LaTeX with figures at 300 dpi minimum. Structure research articles as Abstract, Introduction, Methods, Results, Discussion, and References.
Use the journal's numbered (Vancouver) reference style. Cite sources consecutively in the order they appear, and ensure every reference is complete and retrievable.
Declare all funding sources, conflicts of interest, and ethical approvals (including informed consent and animal-care statements where applicable).